glp 1 and kidney function GLP-1 the kidney: from physiology to pharmacology and outcomes in diabetes Glucagon-like Peptide-1 Receptor Agonists and

What Studies Have NOT Demonstrated in Humans Despite community claims, no controlled human trial has demonstrated: A specific body fat percentage reduction attributable to LR3 IGF-1 cycling A specific lean mass gain figure for the standard 10-day-on / 4-week-off pattern Cardiovascular safety endpoints across repeated cycles Long-term cancer-incidence data for cycled LR3 IGF-1 use Epidemiological data on chronically elevated endogenous IGF-1 has raised theoretical cancer concerns (Yoshida & Delafontaine, 2020), and that concern is one reason community protocols favor short, spaced cycles rather than continuous use

References Abi-Dargham A, Grace A

* Prices + GST if applicable

Int J Genomics